And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
Zymeworks Receives US FDA Approval for Ziihera and $25M 'Milestone Payment' From Jazz Pharmaceuticals (Eligible for $1 Billion+) FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the ...
The U.S. Food AND Drug Administration (FDA) has granted accelerated approval of a new drug for treating bilary tract cancer ...
Jazz Pharmaceuticals (JAZZ) stock and Zymeworks (ZYME) stock gain as FDA clears their cancer therapy Ziihera. Read more here.
Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...
Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...
MADISON, Wis., December 03, 2024--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific ...
Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with ...
Zymeworks (ZYME) announced, with Jazz Pharmaceuticals (JAZZ), that the U.S. FDA has granted accelerated approval of Ziihera 50mg/mL for ...